236 related articles for article (PubMed ID: 32769327)
1. A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka.
Wijesinghe HD; Fernando J; Senarath U; Wijesinghe GK; S Lokuhetty MD
Indian J Pathol Microbiol; 2020; 63(3):388-396. PubMed ID: 32769327
[TBL] [Abstract][Full Text] [Related]
2. Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.
Sable M; Pai TD; Shet T; Patil A; Dhanavade S; Desai SB
Int J Surg Pathol; 2017 May; 25(3):230-237. PubMed ID: 27612858
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma.
Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS
BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
[TBL] [Abstract][Full Text] [Related]
6. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
7. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
8. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic characteristic features of triple negative and nontriple negative breast cancer at a tertiary care hospital.
Mohapatra M
J Cancer Res Ther; 2023; 19(5):1186-1193. PubMed ID: 37787282
[TBL] [Abstract][Full Text] [Related]
10. CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer.
Liu M; Tsang JYS; Lee M; Ni YB; Chan SK; Cheung SY; Hu J; Hu H; Tse GMK
J Clin Pathol; 2018 Nov; 71(11):1007-1014. PubMed ID: 30099407
[TBL] [Abstract][Full Text] [Related]
11. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
12. The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer.
Fernandez AI; Geng X; Chaldekas K; Harris B; Duttargi A; Berry VL; Berry DL; Mahajan A; Cavalli LR; Győrffy B; Tan M; Riggins RB
Breast Cancer Res Treat; 2020 Feb; 179(3):585-604. PubMed ID: 31741180
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.
Karihtala P; Kauppila S; Soini Y; Arja-Jukkola-Vuorinen
BMC Cancer; 2011 Jun; 11():262. PubMed ID: 21693047
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre.
Sharma M; Sharma JD; Sarma A; Ahmed S; Kataki AC; Saxena R; Sharma D
Asian Pac J Cancer Prev; 2014; 15(11):4507-11. PubMed ID: 24969877
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
19. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]